Abstract: Background. Minority populations are disproportionally aff ected by human papilloma virus (HPV) infection. We examined the attitudes of primary care providers serving large minority populations towards the implementation of the HPV vaccine for males in their practices. Design. Cross-sectional survey of randomly selected primary care providers in Brooklyn, N.Y. Results. Ninety-three eligible providers were surveyed, of whom 62% were pediatricians. Sixty-two percent of all participants reported that they were very likely or will defi nitely be off ering the vaccine to their male patients. The rate was higher among providers who reported higher numbers of minority patient population and who acknowledged high risk among their patient population. Conclusions. Primary care providers included in the study were likely to report incorporation of the HPV vaccine for males as part of their regular clinical practice. Their adoption and dissemination of the vaccine will be a signifi cant factor in determining whether its full benefi ts are achieved.
and almost 1% of all sexually active men will have genital warts at one time in their lives, most of these cases occurring among minority men. 7 The HPV vaccine could reduce or eliminate the majority of these cases and reduce the associated morbidity, mortality, and fi nancial burden. [8] [9] [10] HPV types 6 and 11 are the most common types associated with genital warts, although types 16-18 are particularly associated with high risk for penile and anal cancers and a number of oropharyngeal cancers. 11 The HPV vaccine was licensed by the United States Food and Drug Administration (FDA) in 2006 for girls and women for the prevention of cervical, vulvar, and vaginal cancers and genital warts and in October 2009 for use in males ages nine through 26 years for prevention of genital warts, anal and penile cancers caused specifi cally by HPV 16 and 18. 12, 13, 14 In recent years, a signifi cant amount of evidence has been published that supports the effi cacy and the safety of the HPV vaccine among females to prevent HPV-related diseases. [15] [16] [17] Similarly, a number of studies provided evidence that led to FDA approval of the HPV vaccine for use in boys and men. [18] [19] [20] [21] An analysis by Elbasha et al., determined that off ering the HPV vaccine to males between the ages of nine and 26 years could have a considerable public health benefi t and should be considered a cost-eff ective clinical practice. 8 Despite these fi ndings, clinicians have found multiple barriers for implementing the vaccine in their practices including logistical issues (e.g., storage needs), time constraints, limited availability of information about, and overall acceptance of, the vaccine by their patient population. [22] [23] [24] [25] Patient and parent/guardian barriers include limited access to tailored information for patients, cost, cultural barriers, and perceived risks outweigh the perceived benefi ts of the vaccine, among others. 24, [26] [27] [28] Primary care providers (PCP) are the most common regular source of health care in the United States and are on the vanguard of improving health outcomes and reducing health care disparities through the adoption of evidence-based preventive practices such as HPV vaccination. [29] [30] [31] [32] It is essential to understand the factors aff ecting PCPs' implementation of the HPV vaccine for boys and men. This study describes PCPs' knowledge, beliefs, and attitudes towards the delivery of HPV vaccine to boys and men, and the factors that could infl uence providers' utilization of the vaccine.
Methods
Study design and sampling method. We conducted a cross-sectional study of PCPs serving large minority populations at high risk for HPV infection in Brooklyn, New York between June and December 2010. The provider population included pediatricians, family practitioners, and internal medicine physicians serving neighborhoods identifi ed from the American Community Survey 33 as having large minority populations (greater than 30%) in Brooklyn, New York. Other inclusion criteria included: 1) New York State-registered general pediatrician, internal medicine physician, or family practitioner; 2) minimum one half of their patient population belong to minority populations (physician-reported); 3) minimum one third of their patient population is between the ages of nine and 26 years (physician-reported).
An inventory of these providers was created from the New York State Department of Health provider database and medical organization membership lists (i.e., the local Chapters of the American Academy of Pediatrics). Multiple sources were used to increase accuracy. Five-hundred-and-fi ft y-two (552) providers met criteria. A random sample was generated until the proposed sample size of 93 was reached. The sample size was calculated using a 95% confi dence interval. Randomization was stratifi ed by ZIP code of practice and type of provider (pediatrician, family practitioner, or internist) to obtain a proportionally distributed number of subjects in the study.
Survey. A survey was developed entirely by a group of three physicians (pediatrician, internist, and family practitioner) and two behavioral scientists based on the conceptual framework of the Theory of Planned Behavior. 34 The survey included questions in the areas of HPV vaccine for males, including knowledge, beliefs, barriers to administration, and clinical practices. Information to develop the survey was obtained from several sources including the Centers for Disease Control, the National Cancer Institute, and the American Cancer Society, among others. The survey was pilot tested with six physicians eligible to participate in the study. Based on the results, questions were revised as needed and all points made by providers included in the pilot group were addressed. The revised survey was then reviewed by the research team and all further concerns were addressed. The survey also included information on demographic variables, medical training history, and a description of the respondents' patient populations. The time it took to complete the survey averaged 25 to 30 minutes. By the time the survey was developed and implemented, the Food and Drug Administration (FDA) had approved the HPV vaccine for males, but a recommendation for use was not included in any vaccination guidelines or vaccination schedules.
Data collection. Providers randomly selected to participate in the study received the survey by mail, together with an information sheet that explained the study and the eligibility criteria. As proposed by Delnevo et al., we used an up-front-incentive for participating in the study to increase the response rate. 35 The package mailed to the physician included as the incentive the most recent edition of the Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book: Course Textbook, with the mailed survey. If we did not receive the completed questionnaire approximately two weeks aft er the initial mailing, we contacted the physician by mail and by phone. This was repeated at weeks four and six if there was no response. If there was no response aft er eight weeks, we considered that subject a non-responder.
Data were entered, stored and analyzed using IBM SPSS Statistics® version 19. 36 This study was approved by the State University of New York, Downstate Medical Center Institutional Review Board.
Results
Ninety three providers completed the survey out of 168 eligible providers that were contacted. This survey response rate of 55% is similar to other published manuscripts that have used comparable methodology. Ninety-three eligible providers were surveyed, of whom 62% (58) were pediatricians, 21% were internists, and 17% were family practitioners. There was no diff erence in the response rates for these groups. Forty-seven of the participants were female (51%) and the average age was 53 years (range 33-85).
Other socio-demographic data are presented in Table 1 . Over 70% of the providers included in the study reported that at least 75% of their patient population belonged to minority groups, 54% of providers reported that immigrants constituted more than 20% of their patient population, and on average providers reported that approximately 5% of the patient population were uninsured.
Eighty fi ve percent of providers in the study believed that HPV infection and its complications warranted a vaccine, and 86% thought the HPV vaccine is safe, although 82% believed that long-lasting immunity from the vaccine was still not established. Based on their current experience using the HPV vaccine with their eligible female patients, 80% reported that handling of the vaccine, including the storage requirement, was not a diffi culty. Eighty-nine percent (89%) reported that they had suffi cient personnel and equipment to off er the vaccine to their patients, and 79% thought that there were enough local sites to refer their patients for HPV vaccine if they did not off er it in their setting. Sixty-seven percent (67%) of the providers in the study thought the vaccine was too expensive. When asked about the likelihood of their off ering the HPV vaccine to their eligible male patients, 62% of all respondents reported that they were very likely or would defi nitely be off ering the vaccine, 25% would consider it and 13% responded that it was very unlikely that they would be off ering the vaccine to their eligible male patients. Providers who reported having a patient population constituted of 75% or more of minorities were more likely to off er the vaccine than those with a smaller percentage of minority patient population (73% vs. 39% respectively, p=.002), as were providers who acknowledged a high risk of HPV infection among their patient population (72% vs. 50%, p=.05). Further results are shown in Table 2 .
When providers in the study were asked if off ering the HPV vaccine for males in their practice would have any eff ect on their overall utilization of the HPV vaccine, 36% reported that off ering the vaccine to their male patients would not change their use of the vaccine among their female patients, and 46% reported that they would off er the vaccine similarly to males and females. Forty-two percent (42%) of providers thought that off ering the HPV vaccine to boys would have no eff ect on perceptions about whether girls should get the vaccine or the rate of parents' acceptance to vaccinating their daughters. Forty percent (40%) of providers in the study were not sure if it would have any eff ect, and 18% thought that it would increase parents' acceptance of vaccination. We asked providers in the study about their perceived barriers against administering the HPV vaccine to their eligible patients. Twenty four percent of providers cited lack of time to educate their patients about the vaccine as a barrier, and 24% cited cost as a barrier. "Competing priorities, other issues more pressing" was cited as a barrier for recommending the HPV vaccine by 26% of providers surveyed, and 20% cited cultural beliefs (patient/parents/or guardian would not accept the HPV vaccine because of cultural beliefs) as a barrier against recommending HPV vaccine.
Discussion
As the approval by the FDA of the HPV vaccine for boys and men translates into practice, PCPs will be on the frontline in off ering this preventive measure. To the best of our knowledge, this is the fi rst study that looks at attitudes surrounding the implementation of the HPV vaccine for males among PCPs serving large minority populations. Their adoption and administration of the HPV vaccination will be a signifi cant factor in determining whether the full benefi ts of the vaccine are achieved, particularly among high-risk populations. In our study, PCPs had a positive attitude overall towards off ering the HPV vaccine to their eligible male patients and reported being highly likely to incorporate it as part of their regular clinical practice.
A large percentage of providers in the study thought the HPV vaccine was important and regarded it as safe. In addition, the majority believed that the infrastructure in their clinical settings was adequate to manage the requirements of handling the vaccine as well as the added logistical burden on their limited resources. This is particularly important because more than 70% of the providers in the study practice in small private practice settings and, according to the Community Health Survey, more than 50% of minority adults in New York City visit a private doctor for their health care needs (as opposed to large medical centers or outpatient clinics). 37, 38 The positive attitudes of providers in the study off er a great opportunity to distribute the vaccine to a large portion of the eligible population. However, as reported in this and other studies, cost remains a key barrier for providers in off ering the HPV vaccine to their eligible patients. 39 Although a small percentage of our respondents' patient populations were uninsured, coverage for the vaccine varies among patients and insurance policies. Eff orts should be targeted to include the coverage of the HPV vaccine for both eligible females and males to improve access. According to Elbasha et. al. and Kim et. al., expanding coverage for the HPV vaccine to include boys and men is cost-eff ective at conventional thresholds and it could provide substantial public health benefi t. 8, 40 This should encourage public and private insurances to expand coverage and reduce barriers for providing this preventive measure.
Pediatricians and family practitioners in the study were more likely to off er the HPV vaccine to their male patients than were internists. This may be attributed to their more common use of vaccines in general. However, general internists are major providers of primary care to adults in the United States and have a unique opportunity to provide preventive care to their adult patients. Because the FDA has approved the HPV vaccine for adults up to 26 years of age to prevent genital warts and HPV-related cancers, it is necessary to encourage internists to incorporate this service into their regular clinical practices, through the provision of simple and cost-eff ective solutions. In our study, providers identifi ed lack of time, cost, competing priorities, and patient cultural beliefs as barriers for recommending the HPV vaccine to their female patients. We believe these barriers will also play a signifi cant role when recommending the vaccine to males. Improving coverage (i.e., insurance coverage, free vaccination programs), and identifying effi cient and eff ective approaches that will reduce the time providers spend recommending the vaccine (e.g., a patient educator/patient navigator, targeted educational materials) will help diminish these barriers. HPV vaccine information, presented in written or visual media, should be tailored to the population to address their culturally-specifi c beliefs, to be their native or preferred language, and to have a health literacy level that allows the majority of the population to access the information.
Having a large minority patient population and being aware of their patients' risk for HPV-related diseases were factors signifi cantly associated with greater willingness among providers to off er the HPV vaccine to their eligible male patients. Providers in this study served in areas with populations at high risk of HPV and HPV-related diseases, perhaps increasing their understanding of the need for this preventive measure and increasing the likelihood to utilize the vaccine. This fi nding supports our proposal that future work should focus on disseminating clear information to PCPs serving minority populations about the disparities in HPV-related diseases that affl ict minority populations, and the importance of implementing this preventive service while tailoring it to the needs of their particular patient population.
It is possible that providers in the study were overestimating the likelihood that they would be off ering the HPV vaccine to their male patients. The up-front incentive for participating in the study could have contributed to this. While we evaluated self-reported rates, the purpose of this study was to describe the providers' attitudes towards implementing the HPV vaccine for their male patients, and the challenges they foresee when they off er the vaccine. These fi ndings identify areas that should be covered to facilitate the translation of this evidence-based preventive service to their practices.
It is estimated that 3,000 new cases of HPV-related cancer occur among men each year in the U.S., with the majority of them occurring in minority populations, specifi cally Hispanic or Latinos and Blacks. 7 Similarly, it is estimated that 1% of sexually active men in the U.S. have genital warts, and almost 90% of these cases are related to HPV. 40 The use of the HPV vaccine among men has the potential to reduce and eliminate the majority of these cases. Primary care providers will be on the frontlines of this eff ort. Innovative, time-saving, and culturally-tailored interventions should be tested and implemented to facilitate the dissemination of the HPV vaccine among PCPs that serve large minority populations.
